博雅生物(300294) - 2025年3月21日投资者关系活动记录表

Group 1: Business Strategy and Focus - The company has determined to focus on the development of blood products and aims to become a world-class enterprise in this field, with plans to dispose of or divest non-blood product businesses as necessary [2][3] - The company is actively applying for new plasma stations in eligible regions to seize opportunities in the "14th Five-Year Plan" for blood product industry development [2][3] Group 2: Operational Goals and Management - The company is enhancing its plasma station operational management and aims for continuous improvement through organizational restructuring and digital empowerment [3] - The management model involves three business centers with vertical penetration of functions to strengthen integration and improve profitability [3][4] Group 3: Product Development and Market Expansion - The company is committed to an internationalization strategy that includes drug international registration and the introduction of innovative products and advanced technologies [3] - New products such as IVIG (10%) and Tetanus Immunoglobulin are expected to be launched in 2025, while C1 Esterase Inhibitor is anticipated to be available by 2027 [4] Group 4: Market Performance - The company’s PCC market share ranks third in the industry, with significant sales achievements in the chronic disease management project for 2024 [4]